Compare · GH vs HUM
GH vs HUM
Side-by-side comparison of Guardant Health Inc. (GH) and Humana Inc. (HUM): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both GH and HUM operate in Medical Specialities (Health Care), so they compete in similar markets.
- HUM is the larger of the two at $46.80B, about 2.1x GH ($22.13B).
- GH has been more active in the news (15 items in the past 4 weeks vs 6 for HUM).
- Both have 25 recent analyst ratings on file.
- Company
- Guardant Health Inc.
- Humana Inc.
- Price
- -
- -
- Market cap
- $22.13B
- $46.80B
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Medical Specialities
- Medical Specialities
- Exchange
- NASDAQ
- NYSE
- IPO
- 2018
- News (4w)
- 15
- 6
- Recent ratings
- 25
- 25
Guardant Health Inc.
Guardant Health, Inc., a precision oncology company, provides blood tests, data sets, and analytics in the United States and internationally. The company offers Guardant360, Guardant360 CDx, and GuardantOMNI liquid biopsy-based tests for advanced stage cancer; and GuardantINFORM, an in-silico research platform that comprise a clinical-genomic liquid biopsy dataset of advanced cancer patients. It is also developing tests from its LUNAR program for neoadjuvant and adjuvant treatment selection in early-stage cancer patients; LUNAR-2 test for the early detection of cancer in asymptomatic individuals eligible for cancer screening; and GuardantConnect, an integrated software-based solution for clinical and biopharmaceutical customers seeking to connect patients tested with the Guardant360 assay with actionable alterations with potentially relevant clinical trials. In addition, the company offers Guardant Reveal Test for residual disease and recurrence monitoring; Guardant360 tissue genotyping product; and Guardant-19 for use in the detection of the novel coronavirus. Further, it offers development services, including companion diagnostic development and regulatory approval, clinical trial referral, and liquid biopsy testing development and support services to biopharmaceutical companies and medical institutions. Daiichi Sankyo has collaboration with Guardant Health to develop Guardant360 CDx as a companion diagnostic for Enhertu in advanced metastatic non-small cell lung cancer. Guardant Health, Inc. was incorporated in 2011 and is headquartered in Redwood City, California.
Humana Inc.
Humana Inc., together with its subsidiaries, operates as a health and well-being company in the United States. It operates through Retail, Group and Specialty, and Healthcare Services segments. The company offers medical and supplemental benefit plans to individuals. It also has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits. In addition, the company provides commercial fully-insured medical and specialty health insurance benefits comprising dental, vision, and other supplemental health benefits; and administrative services only products to individuals and employer groups, as well as military services, such as TRICARE T2017 East Region contract. Further, it offers pharmacy solutions, provider services, predictive modeling and informatics services, and clinical care services, such as home health and other services to its health plan members, as well as to third parties. As of December 31, 2020, the company had approximately 17 million members in medical benefit plans, as well as approximately 5 million members in specialty products. Humana Inc. was incorporated in 1964 and is headquartered in Louisville, Kentucky.
Latest GH
- Co-Chief Executive Officer Talasaz Amirali sold $6,343,384 worth of shares (37,500 units at $169.16) (SEC Form 4)
- Director Mignone Roberto converted options into 264 shares, increasing direct ownership by 3% to 10,010 units (SEC Form 4)
- Guardant Health to Appeal Federal District Court Judgment
- TwinStrand Biosciences Announces Final Judgment in Patent Infringement Suit Against Guardant Health, Awarding TwinStrand and the University of Washington More Than $245.2 Million in Damages, Accrued Royalties and Interest
- Director Hidalgo Medina Manuel converted options into 232 shares, increasing direct ownership by 5% to 4,788 units (SEC Form 4)
- Director Tariq Musa converted options into 250 shares and sold $18,148 worth of shares (116 units at $156.45), increasing direct ownership by 1% to 11,316 units (SEC Form 4)
- Chief People Officer Monroe Terilyn J. exercised 46,300 shares at a strike of $22.70 and sold $7,645,218 worth of shares (46,300 units at $165.12) (SEC Form 4)
- Co-Chief Executive Officer Eltoukhy Helmy gifted 35,000 shares and received a gift of 35,000 shares (SEC Form 4)
- Co-Chief Executive Officer Talasaz Amirali gifted 75,000 shares and received a gift of 75,000 shares (SEC Form 4)
- Chief Legal Officer Saia John G. gifted 800 shares, decreasing direct ownership by 2% to 38,991 units (SEC Form 4)
Latest HUM
- Humana Names Dr. Shantanu Nundy as Chief Medical Officer
- James P. Holland to Join Humana as Medicaid President
- Humana upgraded by Morgan Stanley with a new price target
- Humana Subsidiary iCare Selected for Family Care and Family Care Partnership Contracts Across Southeast Wisconsin
- Director Smith Paul John was granted 544 units of Humana Common (SEC Form 4)
- Director Crawford Frederick John was granted 544 units of Humana Common (SEC Form 4)
- Humana upgraded by Evercore ISI with a new price target
- Humana upgraded by Leerink Partners with a new price target
- Humana downgraded by Raymond James
- New insider Crawford Frederick John claimed ownership of 21 units of Humana Common (SEC Form 3)